

LISTING OF CLAIMS

1. (Currently amended) An immunostimulatory composition comprising an oligodeoxynucleotide fully encapsulated in a lipid particle comprising a cationic lipid, wherein said oligodeoxynucleotide is a non-sequence specific immunostimulatory sequence including at least one CpG motif or palindromic sequence.
2. (Canceled)
3. (Currently amended) The composition according to claim 1, wherein ~~the nucleic acid polymers~~ said oligodeoxynucleotide includes at least one CpG motif.
4. (Withdrawn) The composition according to claim 1, wherein the nucleic acid polymer has no detectable immunostimulatory activity in the mammal in the absence of the lipid particle.
5. (Previously presented) The composition according to claim 1, wherein said oligodeoxynucleotide consists of deoxynucleotide residues joined by phosphodiester linkages.
6. (Original) The composition according to claim 1, wherein the cationic lipid is selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA and DOGS.
7. (Original) The composition according to claim 1, wherein the lipid particle further comprises an exchangeable steric barrier lipid.
8. (Original) The composition according to claim 7, wherein the exchangeable steric barrier lipid is a PEG-lipid, a PAO-lipid or a ganglioside.
9. (Original) The composition according to claim 1, further comprising a drug or cytotoxic agent.
10. (Original) The composition of claim 9, wherein the drug or cytotoxic agent is associated with the lipid particle.
11. (Original) The composition according to claim 1, further comprising an antigenic molecule selected from among polypeptides, glycolipids and glycopeptides comprising at least one epitope of the target antigen and nucleic acids encoding at least one epitope of the target antigen.
12. (Original) The composition according to claim 11, wherein the antigenic molecule is associated with the lipid particle.
13. (Canceled)

14. (Previously presented) The composition according to claim 11, wherein said oligodeoxynucleotide includes at least one CpG motif.

15. (Withdrawn) The composition according to claim 11, wherein the nucleic acid polymer has no detectable immunostimulatory activity in the mammal in the absence of the lipid particle.

16. (Original) The composition according to claim 11, wherein the oligodeoxynucleotide consists of deoxynucleotide residues joined by phosphodiester linkages.

17. (Original) The composition according to claim 11, wherein the cationic lipid is selected from the among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA and DOGS.

18. (Original) The composition according to claim 11, wherein the lipid particle further comprises an exchangeable steric barrier lipid.

19. (Original) The composition according to claim 17, wherein the exchangeable steric barrier lipid is a PEG-lipid, a PAO-lipid or a ganglioside.

20. (Canceled)

21. (Canceled)